Koichi Ashida
Director/Board Member at Megakaryon Corp.
Profile
Koichi Ashida founded Fast Track Initiative, Inc. in 2004, where he worked as Chief Operating Officer & Partner from 2011 to 2016.
Mr. Ashida also currently works at KBI Biopharma, Inc., as Director, Innovation Network Corporation of Japan, Ltd., as Executive Managing Director from 2016, NapaJen Pharma, Inc., as Director, Megakaryon Corp., as Outside Director, and Atonarp, Inc., as Outside DIrector.
Mr. Ashida also formerly worked at Chiome Bioscience, Inc., as Executive Director from 2005 to 2011, Japan Medical Information Research Institute, Inc., as Director, PRISM BioLab Co., Ltd., as Outside Director, AQUA Therapeutics Co., Ltd., as Director, Quantum Biosystems, Inc., as Outside Director, Create Vaccine Co. Ltd., as Director, SCOHIA PHARMA, Inc., as Outside Director, Monsanto Japan Ltd., as Principal, Bain & Co. Japan, Inc., as Principal, and GE Healthcare Asia, as Principal.
Mr. Ashida received his graduate degree from the University of Tokyo.
Koichi Ashida active positions
Companies | Position | Start |
---|---|---|
Megakaryon Corp.
Megakaryon Corp. Medical/Nursing ServicesHealth Services Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan. | Director/Board Member | - |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Director/Board Member | - |
Innovation Network Corporation of Japan, Ltd.
Innovation Network Corporation of Japan, Ltd. Investment ManagersFinance The Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. Leveraging the rich history of Japanese technological prowess, the INCJ aims to provide financial, technological and management support in order to promote the creation of next-generation businesses through 'open innovation,' or the flow of technology and expertise beyond the boundaries of existing organizational structures. The INCJ will draw on funding as well as management and technological expertise from the public and private sectors. The INCJ is actively reviewing various investment opportunities in areas of environment and energy, electronics and IT, bio-tech, and infrastructure such as water supply, railway service, and nuclear power supply. Each investment will be thoroughly vetted to ensure it meets the exacting standards of the INCJ's Innovation Network Committee, which will make the final investment decisions. The INCJ is capitalized at 92 billion yen, with the Japanese government injecting 82 billion yen and 19 private corporations (refer to details in Appendix below) providing a further 10 billion yen. The government will also provide guarantees up to a total of 800 billion yen for INCJ investments, giving it an investment capability of approximately 900 billion yen (US$10 billion). The INCJ will be established for a period of 15 years. | Private Equity Investor | 2016-06-29 |
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Director/Board Member | - |
Atonarp, Inc.
Atonarp, Inc. Medical SpecialtiesHealth Technology Atonarp, Inc. provides chemical analysis solutions and systems. The firm develops the Smart Spectrometer technology that focus on industrial gas process analytics applications in the energy, pharmaceutical, petrochemical and semiconductor industries. The company was founded by Tomoyoshi Sato and Prakash S. Murthy in November 2009 and is headquartered in Minato-Ku, Japan. | Director/Board Member | - |
Former positions of Koichi Ashida
Companies | Position | End |
---|---|---|
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States. | Founder | 2016-06-29 |
SCOHIA PHARMA, Inc.
SCOHIA PHARMA, Inc. Miscellaneous Commercial ServicesCommercial Services SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe. | Director/Board Member | - |
Create Vaccine Co. Ltd.
Create Vaccine Co. Ltd. BiotechnologyHealth Technology Create Vaccine Co., Ltd. is a holding company that engages in the research and development of vaccines. The firm specializes in the development and marketing of vaccines for tuberculosis. The company was founded on July 31, 2013 and is headquartered in Osaka, Japan. | Director/Board Member | - |
AQUA Therapeutics Co., Ltd.
AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Director/Board Member | - |
░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Koichi Ashida
University of Tokyo | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CHIOME BIOSCIENCE INC. | Health Technology |
Private companies | 15 |
---|---|
Bain & Co. Japan, Inc. | |
GE Healthcare Asia | |
Monsanto Japan Ltd.
Monsanto Japan Ltd. Chemicals: AgriculturalProcess Industries Part of Bayer AG, Monsanto Japan Ltd. is a Japanese company that manufactures a wide range of genetically altered seeds, fertilizers, and agrochemicals. The company is based in Tokyo, Japan. | Process Industries |
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States. | Finance |
Japan Medical Information Research Institute, Inc.
Japan Medical Information Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Japan Medical Information Research Institute, Inc. engages in the collection, analysis, marketing, and consulting of medical information. The company was founded on July 14, 2005 and is headquartered in Tokyo, Japan. | Commercial Services |
PRISM BioLab Co., Ltd.
PRISM BioLab Co., Ltd. Pharmaceuticals: MajorHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Yokohama, Japan. | Health Technology |
Megakaryon Corp.
Megakaryon Corp. Medical/Nursing ServicesHealth Services Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan. | Health Services |
Quantum Biosystems, Inc.
Quantum Biosystems, Inc. BiotechnologyHealth Technology Quantum Biosystems, Inc. is a holding company that develops single-molecule DNA sequencers. It develops and commercializes sequencers based on quantum mechanics. The company was founded by Toshihiko Honkura and Masateru Taniguchi on January 7, 2013 and is headquartered in Osaka, Japan. | Health Technology |
AQUA Therapeutics Co., Ltd.
AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Health Technology |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Health Technology |
Create Vaccine Co. Ltd.
Create Vaccine Co. Ltd. BiotechnologyHealth Technology Create Vaccine Co., Ltd. is a holding company that engages in the research and development of vaccines. The firm specializes in the development and marketing of vaccines for tuberculosis. The company was founded on July 31, 2013 and is headquartered in Osaka, Japan. | Health Technology |
Innovation Network Corporation of Japan, Ltd.
Innovation Network Corporation of Japan, Ltd. Investment ManagersFinance The Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. Leveraging the rich history of Japanese technological prowess, the INCJ aims to provide financial, technological and management support in order to promote the creation of next-generation businesses through 'open innovation,' or the flow of technology and expertise beyond the boundaries of existing organizational structures. The INCJ will draw on funding as well as management and technological expertise from the public and private sectors. The INCJ is actively reviewing various investment opportunities in areas of environment and energy, electronics and IT, bio-tech, and infrastructure such as water supply, railway service, and nuclear power supply. Each investment will be thoroughly vetted to ensure it meets the exacting standards of the INCJ's Innovation Network Committee, which will make the final investment decisions. The INCJ is capitalized at 92 billion yen, with the Japanese government injecting 82 billion yen and 19 private corporations (refer to details in Appendix below) providing a further 10 billion yen. The government will also provide guarantees up to a total of 800 billion yen for INCJ investments, giving it an investment capability of approximately 900 billion yen (US$10 billion). The INCJ will be established for a period of 15 years. | Finance |
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Atonarp, Inc.
Atonarp, Inc. Medical SpecialtiesHealth Technology Atonarp, Inc. provides chemical analysis solutions and systems. The firm develops the Smart Spectrometer technology that focus on industrial gas process analytics applications in the energy, pharmaceutical, petrochemical and semiconductor industries. The company was founded by Tomoyoshi Sato and Prakash S. Murthy in November 2009 and is headquartered in Minato-Ku, Japan. | Health Technology |
SCOHIA PHARMA, Inc.
SCOHIA PHARMA, Inc. Miscellaneous Commercial ServicesCommercial Services SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe. | Commercial Services |
- Stock Market
- Insiders
- Koichi Ashida